Skip to main content
Log in

Aspirin for Myocardial Infarction

Clinical Pharmacokinetic Considerations

Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy — I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106

    Article  Google Scholar 

  2. Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: theory and practice. Blood 1994; 83: 885–98

    PubMed  CAS  Google Scholar 

  3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60

    Google Scholar 

  4. Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320–31

    Article  Google Scholar 

  5. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets — I: acetylation of a paniculate fraction protein. J Clin Invest 1975; 56: 624–32

    Article  PubMed  CAS  Google Scholar 

  6. Roth GJ, Siok CJ. Acetylation of the NH2-terminal serine of prostaglandin synthetase by aspirin. J Biol Chem 1978; 253: 3782–4

    PubMed  CAS  Google Scholar 

  7. Marcus AJ, Weksler BB, Jaffe EA. Enzymatic conversion of prostaglandin endoperoxide H2 and arachidonic acid to prostacyclin by cultured human endothelial cells. J Biol Chem 1978; 253: 7138–41

    PubMed  CAS  Google Scholar 

  8. Czervionke RL, Smith JB, Fry GL, et al. Inhibition of prostacyclin by treatment of endothelium with aspirin. J Clin Invest 1979; 63: 1089–92

    Article  PubMed  CAS  Google Scholar 

  9. Fitzgerald DJ, Catella F, Roy L, et al. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142–50

    Article  PubMed  CAS  Google Scholar 

  10. Becker RC, Gore JM. Adjuvant antiplatelet strategies in coronary thrombolysis. Circulation 1991; 87: 1115–7

    Article  Google Scholar 

  11. Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischaemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992; 19: 671–7

    Article  PubMed  CAS  Google Scholar 

  12. Grines CL. Thrombolytic, antiplatelet, and antithrombotic agents. Am J Cardiol 1992; 70: 18–26

    Article  Google Scholar 

  13. Norris RM, White HD, Cross DB, et al. Aspirin does not improve early arterial patency after streptokinase treatment for acute myocardial infarction. Br Heart J 1993; 69: 492–5

    Article  PubMed  CAS  Google Scholar 

  14. Meijer A, Freek WA, Verheugt MD, et al. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Circulation 1993; 87: 1524–30

    Article  PubMed  CAS  Google Scholar 

  15. Sils D, Rodgers SE, Lloyd JV, et al. Inhibition of platelet aggregation and thromboxane production by low concentrations of aspirin in vitro. Clin Sci 1988; 74: 491–7

    PubMed  CAS  Google Scholar 

  16. Wilson KM, Siebert DM, Duncan EM, et al. Effect of aspirin infusions on platelet function in humans. Clin Sci 1990; 79: 37–42

    PubMed  CAS  Google Scholar 

  17. Bochner F, Williams DB, Morris PMA, et al. Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur J Clin Pharmacol 1988; 35: 287–94

    Article  PubMed  CAS  Google Scholar 

  18. Rowland M, Riegelman S, Harris PA, et al. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci 1972; 61: 379–85

    Article  PubMed  CAS  Google Scholar 

  19. Siebert DJ, Bochner F, Imhoff DM, et al. Aspirin kinetics and platelet aggregation in man. Clin Pharmacol Ther 1983; 33: 367–74

    Article  PubMed  CAS  Google Scholar 

  20. Ross-Lee LM, Elms MJ, Cham BE, et al. Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function. Eur J Clin Pharmacol 1982; 23: 545–51

    Article  PubMed  CAS  Google Scholar 

  21. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. N Engl J Med 1984; 311: 1206–11

    Article  PubMed  CAS  Google Scholar 

  22. Bochner F, Somogyi AA, Wilson KM. Bioinequivalence of four l00mg oral aspirin formulations in healthy volunteers. Clin Pharmacokinet 1991; 21: 394–9

    Article  PubMed  CAS  Google Scholar 

  23. Jiminez AJ, Stubbs ME, Toiler GH, et al. Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men. Am J Cardiol 1992; 69: 258–62

    Article  Google Scholar 

  24. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366–72

    Article  PubMed  CAS  Google Scholar 

  25. Vanags D, Rodgers SE, Lloyd JV, et al. The antiplatelet effect of daily low dose enteric-coated aspirin in man: a time course of onset and recovery. Thromb Res 1990; 59: 995–1005

    Article  PubMed  CAS  Google Scholar 

  26. Zhang CL, Wilson KM, Stafford I, et al. Absorption kinetics of low dose aspirin in patients with evolving acute myocardial infarction. Drug Invest 1994; 7: 169–74

    Article  CAS  Google Scholar 

  27. Gibaldi M. Biopharmaceutics and clinical pharmacokinetics. 4th ed. Philadelphia: Lea & Febiger, 1991: 31

    Google Scholar 

  28. Hoffman W, Forster W Two year Cottbus reinfarction study with 30 mg aspirin per day. Prostaglandins Leukot Essent Fatty Acids 1991; 44: 159–69

    Article  PubMed  CAS  Google Scholar 

  29. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30

    Article  Google Scholar 

  30. Husted SE, Kraemmer Nielsen H, Krussell LR, et al. Acetylsalicylic acid 100 mg and 1000 mg daily in acute myocardial infarction suspects: a placebo-controlled trial. J Intern Med 1989; 226: 303–10

    Article  PubMed  CAS  Google Scholar 

  31. Verheugt FWA, van de Laarse A, Funke-Kupper AJ, et al. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 1990; 66: 267–70

    Article  PubMed  CAS  Google Scholar 

  32. Ali M, McDonald JWD, Thiessen N, et al. Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin. Stroke 1980; 11: 9–13

    Article  PubMed  CAS  Google Scholar 

  33. Bochner F, Lloyd JV. Is there an optimal dose and formulation of aspirin to prevent arterial thrombo-embolism in man? Clin Sci 1986; 71: 625–31

    PubMed  CAS  Google Scholar 

  34. Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med 1992; 327: 175–81

    Article  PubMed  CAS  Google Scholar 

  35. Hirsh J, Dalen JE, Fuster V, et al. Aspirin and other platelet-active drugs: the relationship between dose, effectiveness and side effects. Chest 1992; 102 Suppl. 4: 327S–36S

    PubMed  CAS  Google Scholar 

  36. Jakubowski JA, Stampfer MJ, Vaillancourt R, et al. Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase. J Lab Clin Med 1986; 108: 616–21

    PubMed  CAS  Google Scholar 

  37. Clarke RJ, Mayo G, Price P, et al. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137–41

    Article  PubMed  CAS  Google Scholar 

  38. Bochner F, Siebert DM, Rodgers SE, et al. Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production. Thromb Haemost 1989; 61: 211–6

    PubMed  CAS  Google Scholar 

  39. Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983; 61: 1081–5

    PubMed  Google Scholar 

  40. ACC/AHA Task Force Report. Guidelines for the early management of patients with acute myocardial infarction. J Am Coll Cardiol 1990; 16: 249–92

    Google Scholar 

  41. Ridker PM, Herbert PR, Fuster V, et al. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? Lancet 1993; 341: 1574–7

    Article  PubMed  CAS  Google Scholar 

  42. Wyllie HR, Dunn FG. Pre-hospital opiate and aspirin administration in patients with suspected myocardial infarction. BMJ 1994; 308: 760–1

    Article  PubMed  CAS  Google Scholar 

  43. Basinski A, Naylor CD. Aspirin and fibrinolysis. Lancet 1988; 2: 1188–9

    Article  PubMed  CAS  Google Scholar 

  44. Basinski A, Naylor CD. Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for synergy. J Clin Epidemiol 1991; 44: 1085–96

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bochner, F., Lloyd, J.V. Aspirin for Myocardial Infarction. Clin. Pharmacokinet. 28, 433–438 (1995). https://doi.org/10.2165/00003088-199528060-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199528060-00001

Keywords

Navigation